BioCentury | Dec 14, 2009
Financial News

Therasis completes venture financing

...New York, N.Y. Business: Cancer Date completed: 12/8/09 Type: Venture financing Raised: $12 million Investor: Tilocor Life Sciences...
BioCentury | Dec 9, 2009
Financial News

Therasis secures $12 million

Cancer company Therasis Inc. (New York, N.Y.) secured $12 million in a series A round from Tilocor Life Science. Therasis plans to develop a cancer pipeline using its Therasis Filter drug discovery technology, which identifies...
BioCentury | Nov 23, 2009
Financial News

Xigen completes venture financing

...Lausanne, Switzerland Business: Cardiovascular, Cancer Type: Venture financing Raised: CHF20 million ($19.8 million) Investor: Tilocor Life Sciences...
BioCentury | Nov 17, 2009
Financial News

Xigen raises CHF20 million

Xigen S.A. (Lausanne, Switzerland) said Monday that it raised CHF20 million ($19.8 million) earlier this year in a series B round led by existing investor Tilocor Life Science. Xigen's XG-102 , an inhibitor of c-jun N-terminal...
BioCentury | Sep 7, 2005
Financial News

Xigen raises $21.1 million

...Lausanne, Switzerland) raised CHF 26 million ($21.1 million) in a series A round led by Tilocor Life Sciences...
Items per page:
1 - 5 of 5
BioCentury | Dec 14, 2009
Financial News

Therasis completes venture financing

...New York, N.Y. Business: Cancer Date completed: 12/8/09 Type: Venture financing Raised: $12 million Investor: Tilocor Life Sciences...
BioCentury | Dec 9, 2009
Financial News

Therasis secures $12 million

Cancer company Therasis Inc. (New York, N.Y.) secured $12 million in a series A round from Tilocor Life Science. Therasis plans to develop a cancer pipeline using its Therasis Filter drug discovery technology, which identifies...
BioCentury | Nov 23, 2009
Financial News

Xigen completes venture financing

...Lausanne, Switzerland Business: Cardiovascular, Cancer Type: Venture financing Raised: CHF20 million ($19.8 million) Investor: Tilocor Life Sciences...
BioCentury | Nov 17, 2009
Financial News

Xigen raises CHF20 million

Xigen S.A. (Lausanne, Switzerland) said Monday that it raised CHF20 million ($19.8 million) earlier this year in a series B round led by existing investor Tilocor Life Science. Xigen's XG-102 , an inhibitor of c-jun N-terminal...
BioCentury | Sep 7, 2005
Financial News

Xigen raises $21.1 million

...Lausanne, Switzerland) raised CHF 26 million ($21.1 million) in a series A round led by Tilocor Life Sciences...
Items per page:
1 - 5 of 5